Evidence map›Paper›PMID 41541792›Full record

ArticleComputational and structural biotechnology journal2026

Sequence optimization of a DNA aptamer inhibiting COVID-19 infection guided by analysis of secondary structure distribution.

Maria Izabel Muniz, Thomas Carzaniga, Giovanni Nava, Luca Casiraghi, Davide Giana, Stefano Rocca, Alessandro Pedretti, Jessica Dellavedova, Paolo Ciana, Tommaso Bellini and 1 more

Abstract read
In one paragraph

Article in Computational and structural biotechnology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria Izabel MunizDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Segrate, Italy.
Thomas CarzanigaDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Segrate, Italy.
Giovanni NavaDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Segrate, Italy.
Luca CasiraghiDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Segrate, Italy.
Davide GianaDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Segrate, Italy.
Stefano RoccaDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, Milan, Italy.
Alessandro PedrettiDepartment of Pharmaceutical Sciences, Università degli Studi di Milano, Milan, Italy.
Jessica DellavedovaDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Paolo CianaDepartment of Health Sciences, Università degli Studi di Milano, Milan, Italy.
Tommaso BelliniDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Segrate, Italy.
Marco BuscagliaDepartment of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano, Segrate, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The post-SELEX optimization of nucleic acid aptamers is often hindered by conformational ambiguity, as the specific functional structure is typically unknown. This study presents a combined computational and experimental framework to address this challenge, using an aptamer that inhibits the SARS-CoV-2/ACE2 interaction as a model system. We analyzed the secondary structure ensembles of a pool of aptamer candidates from an initial screening, employing kinetic and structural clustering alongside a novel nucleotide-structure similarity score. By correlating structural similarity patterns with measured inhibition data, we identified a specific structural cluster likely responsible for the inhibitory function. This insight guided the rational design of a new, truncated aptamer providing a length reduction from 76 to 67 nucleotides, engineered to maximize its similarity to this functional cluster. Experimental validation using a label-free biosensor confirmed that the novel aptamer, although shorter, maintained or enhanced inhibition against multiple SARS-CoV-2 RBD variants compared with the original aptamer, yielding a relative inhibition increase of 71 % for the WT variant. This work demonstrates an effective strategy to guide aptamer optimization by integrating computational structural analysis with initial functional screening data, thereby reducing experimental efforts and accelerating the development of high-performance aptamers.

Indexed as

COVID-19DNA aptamersFree-energy landscapeLabel-free biosensorOptimizationSecondary structures

Identifiers

PMID41541792
PMCPMC12800427

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.